Table I.
Baseline characteristics, stratified by treatment group.
| Factor | PTI N=27 |
No PTI N=95 |
P-Value |
|---|---|---|---|
| Demographics
| |||
| Age (mean) | 72.0±9.9 | 69.8±9.8 | 0.425 |
| Gender (% Male) | 22 (81.5%) | 72 (75.8%) | 0.613 |
| Ethnicity (% Minority) | 5 (18.5%) | 19 (20.0%) | 1.000 |
|
Medical History | |||
| Diabetes mellitus | 22 (81.5%) | 79 (83.2%) | 0.781 |
| Renal Insufficiency | 8 (29.6%) | 37 (38.9%) | 0.499 |
| End-Stage Renal Disease | 4 (14.8%) | 22 (23.2%) | 0.433 |
| Hypertension | 21 (77.8%) | 83 (87.4%) | 0.351 |
| Hyperlipidemia | 17 (63.0%) | 47 (49.5%) | 0.308 |
| Prior Myocardial Infarction | 8 (29.6%) | 32 (33.7%) | 0.870 |
| Coronary Artery Disease | 19 (70.4%) | 63 (66.3%) | 0.870 |
| Coronary Artery Bypass | 5 (18.5%) | 30 (31.6%) | 0.232 |
| Chronic Obstructive Pulm. Dis. | 5 (18.5%) | 7 (7.4%) | 0.135 |
| Cerebral Vascular Accident | 4 (14.8%) | 12 (12.6%) | 0.752 |
| Tobacco Smoking History | 14 (51.9%) | 45 (47.4%) | 0.828 |
| Warfarin Therapy | 10 (37.0%) | 16 (16.8)% | 0.046 |
| Statin Therapy | 11 (40.7%) | 48 (50.5%) | 0.497 |
| B-Blocker Therapy | 14 (51.9%) | 59 (62.1%) | 0.461 |
| Anti-Platelet Therapy | 20 (74.1%) | 40 (42.1%) | 0.025 |
PTI: prior tibial intervention; nPTI: no prior tibial intervention.